FCER2 and colitis: In a mouse model of colitis, intraperitoneal injection of BMMSCs could regulate the immunomodulatory effects of B cells by upregulating IL-10 expression, induce a regulatory B-cell (Breg) population characterized by CD23 and CD43 phenotypic markers, increase the number of CD23+, CD43+, and Breg cells, reduce the clinical and pathological severity of colitis in mice (Chen et al., 2019a).